These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1283750)
41. Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports. Kubota K; Hasumi Y; Numata A; Tukazaki T; Horie K; Hashimoto K; Yokota H J Palliat Med; 2013 Jun; 16(6):596-7. PubMed ID: 23600413 [No Abstract] [Full Text] [Related]
42. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center. Walter M; Hansen E; Hamid S; Carozza D; Mann G; Roche C; George A; Attwood K; Case A J Pain Symptom Manage; 2024 Jan; 67(1):20-26. PubMed ID: 37769820 [TBL] [Abstract][Full Text] [Related]
43. [Effects of octreotide on small bowel obstructions in rats]. Cho JH; Kang HG; Kim SH; Lee HS; Lee KR; Kang HY Korean J Gastroenterol; 2003 Oct; 42(4):283-8. PubMed ID: 14634347 [TBL] [Abstract][Full Text] [Related]
47. [Treatment with octreotide for functional obstructions in scleroderma]. Emmerich J; Roux ME; Capron L; Fiessinger JN Presse Med; 1992 Feb; 21(7):316-7. PubMed ID: 1532651 [No Abstract] [Full Text] [Related]
48. Octreotide for malignant bowel obstruction: commentary on Currow et al. Mercadante S J Pain Symptom Manage; 2015 May; 49(5):813. PubMed ID: 25863013 [No Abstract] [Full Text] [Related]
49. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient]. Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560 [TBL] [Abstract][Full Text] [Related]
51. Palliation of gastrointestinal obstruction. Tradounsky G Can Fam Physician; 2012 Jun; 58(6):648-52, e317-21. PubMed ID: 22859627 [No Abstract] [Full Text] [Related]
52. An unusual case of malignant gastro-intestinal obstruction in advanced cervical cancer. Lübbe AS; Stange JH J Cancer Res Clin Oncol; 2002 Mar; 128(3):171-2. PubMed ID: 11935305 [No Abstract] [Full Text] [Related]
53. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210 [TBL] [Abstract][Full Text] [Related]
54. [Application of sandostatin in malignant bowel obstruction]. Li J; Jing ML; Shen L Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794 [TBL] [Abstract][Full Text] [Related]
55. Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide. Cullen JJ; Eagon JC; Kelly KA Dig Dis Sci; 1994 Jun; 39(6):1179-84. PubMed ID: 7515341 [TBL] [Abstract][Full Text] [Related]
56. The role of octreotide in palliative care. Mercadante S J Pain Symptom Manage; 1994 Aug; 9(6):406-11. PubMed ID: 7525789 [TBL] [Abstract][Full Text] [Related]
57. The palliative effects of octreotide in cancer patients. Dean A Chemotherapy; 2001; 47 Suppl 2():54-61. PubMed ID: 11275702 [TBL] [Abstract][Full Text] [Related]
58. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide. Myers J; Tamber A; Farhadian M J Pain Symptom Manage; 2010 Apr; 39(4):e1-3. PubMed ID: 20153136 [No Abstract] [Full Text] [Related]